Despite a 149.2% revenue increase in 2025Q4, the company reported a negative gross margin of -3.3% as R&D expenditures of $817.9K continue to overwhelm top-line growth.
| Sales/Revenue | 248.27K | 52.01K | 290.56K | 0 | 84.18K | 44.92K | 0 |
| Revenue Growth % | 377.39% | -82.1% | - | -100% | 87.38% | - | - |
| Cost of Goods Sold | 937.82K | 22.73K | 2.82K | 81.03K | 2.59K | 3.5K | 0 |
| COGS % of Revenue | 377.74% | 43.71% | 0.97% | - | 3.08% | 7.78% | - |
| Gross Profit | -689.55K | 52.38K | 381.92K | -81.03K | 81.59K | 41.43K | 0 |
| Gross Margin % | -277.74% | 100.72% | 131.44% | - | 96.92% | 92.22% | - |
| Gross Profit Growth % | -1416.44% | -86.29% | 571.31% | -199.32% | 96.94% | - | - |
| Operating Expenses | 2.83M | 1.87M | 1.58M | 1.62M | 937.15K | 891.67K | 480.22K |
| OpEx % of Revenue | 1138.22% | 3598.57% | 542.16% | - | 1113.29% | 1984.88% | - |
| Selling, General & Admin | 1.12M | 1.27M | 370.67K | 443.29K | 435.31K | 116.99K | 29.72K |
| SG&A % of Revenue | 451.7% | 2433.79% | 127.57% | - | 517.13% | 260.43% | - |
| Research & Development | 1.7M | 1.43M | 1.2M | 1.13M | 806.45K | 784.2K | 323.98K |
| R&D % of Revenue | 683.6% | 2747.51% | 414.59% | - | 958.03% | 1745.65% | - |
| Other Operating Expenses | 7.25K | -823.1K | 0 | 41.26K | -304.61K | -9.52K | 126.51K |
| Operating Income | -3.52M | -2.63M | -3.2M | -1.7M | -1.4M | -1M | -480.22K |
| Operating Margin % | -1415.96% | -5049.84% | -1100.96% | - | -1661.39% | -2233% | - |
| Operating Income Growth % | -33.86% | 17.9% | -88.53% | -21.33% | -39.42% | -108.89% | - |
| EBITDA | -3.34M | -2.53M | -3.12M | -1.4M | -1.15M | -782.14K | -382.99K |
| EBITDA Margin % | -1346.04% | -4873.73% | -1074.29% | - | -1371.62% | -1741.08% | - |
| EBITDA Growth % | -31.85% | 18.8% | -122.41% | -21.55% | -47.62% | -104.22% | - |
| D&A (Non-Cash Add-back) | 173.58K | 91.59K | 77.47K | 293.32K | 243.92K | 220.99K | 97.22K |
| EBIT | -3.52M | -1.88M | -3.02M | -1.39M | -1.29M | -997.69K | -446.85K |
| Net Interest Income | 78.83K | 222.5K | 174.54K | -89.25K | -85.07K | 0 | -20.25K |
| Interest Income | 94.83K | 237.7K | 212.72K | 1.52K | 2.51K | 79.71K | 20.06K |
| Interest Expense | 16K | 15.2K | 38.18K | 90.77K | 87.58K | 79.71K | 0 |
| Other Income/Expense | 456.8K | 739.13K | 122.21K | -572.86K | -128.34K | -400.12K | -152.39K |
| Pretax Income | -3.06M | -1.89M | -3.08M | -2.27M | -1.53M | -1.4M | -632.61K |
| Pretax Margin % | -1231.97% | -3628.58% | -1058.9% | - | -1822.31% | -3123.68% | - |
| Income Tax | 0 | 0 | 486 | 1.19K | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.02% | -0.05% | 0% | 0% | 0% |
| Net Income | -3.05M | -1.88M | -3.13M | -2.27M | -1.53M | -1.47M | -632.61K |
| Net Margin % | -1227.07% | -3621.15% | -1077.85% | - | -1822.31% | -3266.07% | - |
| Net Income Growth % | -61.77% | 39.87% | -37.92% | -48.02% | -4.55% | -131.93% | - |
| Net Income (Continuing) | -3.06M | -1.89M | -3.13M | -2.27M | -1.53M | -1.47M | -632.61K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 309.22K | 56.93K | -724 | -509 | -325 | -140 | 0 |
| EPS (Diluted) | -0.26 | -0.16 | -0.29 | -0.30 | -0.22 | -0.25 | -0.11 |
| EPS Growth % | -62.5% | 44.83% | 3.33% | -36.36% | 12% | -127.27% | - |
| EPS (Basic) | -0.26 | -0.16 | -0.29 | -0.30 | -0.22 | -0.25 | -0.08 |
| Diluted Shares Outstanding | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M | 5.9M | 5.55M |
| Basic Shares Outstanding | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M | 5.9M | 5.55M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Insufficient liquidity for operations
As reported in recent financial filings, GDTC achieved a 149.2% revenue increase in 2025Q4, yet the absolute figure remains nominal at $130.6K, underscoring that current top-line growth is driven by incidental research activities rather than a sustainable, volume-based commercial product pipeline or recurring market demand.
The volatility in quarterly revenue suggests that the company relies on sporadic grants or service agreements that lack predictability. Investors should monitor whether these figures represent genuine platform validation or merely non-core funding that fails to signal a transition toward commercial viability.
Based on the provided income statement data, GDTC's gross margin experienced a sharp contraction to -3.3% in 2025Q4, reflecting the high cost of specialized biological reagents and cleanroom maintenance that currently overwhelm the company's limited ability to generate revenue from its early-stage research platform.
The erratic nature of these margins indicates that the company has not yet achieved the manufacturing efficiencies required for allogeneic cell therapy. Until the company can stabilize its cost of goods sold relative to its research output, profitability will likely remain elusive.
According to the latest quarterly results, R&D expenditures reached $817.9K, which significantly exceeds total revenue, highlighting a cost structure that is heavily weighted toward clinical development and laboratory overhead rather than scalable commercial operations or efficient administrative expense management during this pre-clinical phase.
The company's reliance on high-cost R&D inputs suggests that any delay in clinical trial milestones will directly exacerbate the existing burn rate. Management appears to be prioritizing platform development over cost discipline, which is typical for the sector but poses significant risks to long-term solvency.
As indicated by the company's financial statements, the combination of a $1.8M operating loss in 2025Q4 and a limited cash position suggests that GDTC faces a precarious path forward, with the potential for significant shareholder dilution or a total cessation of clinical activities if funding fails.
Short-sellers would likely focus on the widening gap between operating expenses and revenue, which suggests that the current business model is not self-sustaining. The lack of a clear path to commercialization, combined with the high cash burn, warrants further investigation into the company's ability to secure necessary capital.
Quick answers to the most common questions about buying GDTC stock.
For fiscal year 2025, CytoMed Therapeutics Limited (GDTC) reported total revenue of $0.2M.
CytoMed Therapeutics Limited (GDTC) reported a net loss of $3.0M for the fiscal year ending 2025.
CytoMed Therapeutics Limited (GDTC) reported an operating income of $-3.5M, resulting in an operating profit margin of -1416.0%. This margin reflects the operational efficiency of the business before interest and taxes.
CytoMed Therapeutics Limited (GDTC) generated $-0.7M in gross profit for the year, representing a gross profit margin of -277.7%. This demonstrates the company's core pricing power and production efficiency.